New Age Alpha Advisors LLC Acquires 19,983 Shares of Amgen Inc. (NASDAQ:AMGN)

New Age Alpha Advisors LLC increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 55,508.3% in the fourth quarter, Holdings Channel.com reports. The fund owned 20,019 shares of the medical research company’s stock after buying an additional 19,983 shares during the quarter. New Age Alpha Advisors LLC’s holdings in Amgen were worth $5,218,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Loomis Sayles & Co. L P raised its stake in shares of Amgen by 6.6% during the third quarter. Loomis Sayles & Co. L P now owns 854 shares of the medical research company’s stock valued at $275,000 after acquiring an additional 53 shares in the last quarter. Quantbot Technologies LP bought a new stake in Amgen during the 3rd quarter valued at $150,000. Public Sector Pension Investment Board lifted its holdings in shares of Amgen by 14.0% in the 3rd quarter. Public Sector Pension Investment Board now owns 23,547 shares of the medical research company’s stock worth $7,587,000 after buying an additional 2,900 shares during the period. Providence Wealth Advisors LLC grew its position in shares of Amgen by 2.0% during the 3rd quarter. Providence Wealth Advisors LLC now owns 5,521 shares of the medical research company’s stock worth $1,745,000 after buying an additional 110 shares in the last quarter. Finally, Rockefeller Capital Management L.P. grew its position in shares of Amgen by 1.1% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 452,590 shares of the medical research company’s stock worth $145,800,000 after buying an additional 4,901 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of AMGN opened at $306.95 on Friday. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The stock has a 50-day moving average of $301.08 and a two-hundred day moving average of $298.38. The stock has a market cap of $164.90 billion, a P/E ratio of 40.66, a P/E/G ratio of 2.63 and a beta of 0.53. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. As a group, research analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be paid a $2.38 dividend. The ex-dividend date is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.10%. Amgen’s payout ratio is currently 126.09%.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $324.00 price objective on shares of Amgen in a research note on Friday, January 24th. StockNews.com raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Johnson Rice set a $294.00 price objective on shares of Amgen in a report on Wednesday, March 5th. Truist Financial lowered their target price on Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a report on Wednesday, January 8th. Finally, Citigroup reissued a “neutral” rating on shares of Amgen in a research report on Wednesday, February 5th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $314.04.

Insider Transactions at Amgen

In other Amgen news, EVP David M. Reese sold 25,225 shares of the stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the sale, the executive vice president now directly owns 36,922 shares of the company’s stock, valued at approximately $11,240,533.68. This trade represents a 40.59 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jonathan P. Graham sold 25,045 shares of the business’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the transaction, the executive vice president now directly owns 28,987 shares of the company’s stock, valued at approximately $8,496,669.44. This trade represents a 46.35 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 69,341 shares of company stock worth $20,644,335 over the last 90 days. 0.69% of the stock is currently owned by company insiders.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.